Provided by Tiger Trade Technology Pte. Ltd.

Alkermes PLC

43.94
-2.7750-5.94%
Volume:1.43M
Turnover:64.19M
Market Cap:7.37B
PE:113.17
High:46.53
Open:46.51
Low:43.59
Close:46.71
52wk High:55.67
52wk Low:26.99
Shares:167.76M
Float Shares:155.00M
Volume Ratio:1.01
T/O Rate:0.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3882
EPS(LYR):1.43
ROE:3.85%
ROA:4.20%
PB:4.08
PE(LYR):30.72

Loading ...

Alkermes to join Goldman Sachs Global Healthcare Conference fireside chat

Reuters
·
Jun 04

Is Alkermes’ (ALKS) New LYBALVI Real-World Data Quietly Reframing Its Psychiatry Investment Story?

Simply Wall St.
·
Jun 03

Alkermes Chief Medical Officer Craig Hopkinson sells 9,000 shares for $375,044‬

Reuters
·
Jun 02

Alkermes VP Finance Samuel Joseph Parisi disposes of 16,217 shares for $686,807.86

Reuters
·
May 30

Needham Reiterates Buy Rating on Alkermes as Preclinical ALKS 7290 Data Support Unchanged $50 Price Target

TIPRANKS
·
May 29

Alkermes presents Phase 2 Vibrance-1 data on alixorexton in narcolepsy type 1 at ASCP meeting

Reuters
·
May 26

Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting

THOMSON REUTERS
·
May 26

Alkermes presents real-world study comparing Lybalvi versus olanzapine adherence, relapse proxies

Reuters
·
May 21

Alkermes shareholders approve 2018 stock plan share increase by 5.9 million

Reuters
·
May 21

Alkermes Advances Phase 3 Narcolepsy Study With ALKS 2680, Adding a New Catalyst to Its Pipeline

TIPRANKS
·
May 16

Alkermes Is Maintained at Outperform by Baird

Dow Jones
·
May 13

Sector Update: Healthcare Stocks Advance Late Afternoon

MT Newswires Live
·
May 13

Alkermes' (NASDAQ:ALKS) Conservative Accounting Might Explain Soft Earnings

Simply Wall St.
·
May 13

Stock Track | Alkermes Soars 6.37% Intraday on Positive Phase 3 Trial Results for Lumryz in Idiopathic Hypersomnia

Stock Track
·
May 13

Alkermes Phase 3 Trial Meets Primary Endpoint for Hypersomnia Treatment

MT Newswires Live
·
May 12

Analysts Conflicted on These Healthcare Names: Cronos Group (CRON), Savara (SVRA) and Alkermes (ALKS)

TIPRANKS
·
May 12

BRIEF-Alkermes Announces Positive Topline Results From Revitalyz Phase 3 Study Evaluating Lumryz

Reuters
·
May 12

Alkermes says Phase 3 REVITALYZ trial shows LUMRYZ improves idiopathic hypersomnia sleepiness

Reuters
·
May 12

Alkermes Plc - May Not Market Lumryz for Ih Before March 1, 2028

THOMSON REUTERS
·
May 12

Alkermes Plc - Lumryz Meets All Primary and Key Secondary Endpoints in Revitalyz Phase 3 Study

THOMSON REUTERS
·
May 12